Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotera Health CoSHC +2.43%76 Intrinsic Value: Projected FCF is $2.95 as of Sep. 15, 2026. GuruFocus rates SHC with a GF Score™ of 76/100 and a GF Value™ of $16.45 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 106 Medical Diagnostics & Research companies, Sotera Health Co ranks worse than 90.57% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-15), Sotera Health Co's Intrinsic Value: Projected FCF is $2.95. The stock price of Sotera Health Co is $18.98. Therefore, Sotera Health Co's Price-to-Intrinsic-Value-Projected-FCF of today is 6.4.
The historical rank and industry rank for Sotera Health Co's Intrinsic Value: Projected FCF or its related term are showing as below:
SHC'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 5.3 Med: 6.02 Max: 6.89
Current: 6.43
During the past 8 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Sotera Health Co was 6.89. The lowest was 5.30. And the median was 6.02.
SHC's Price-to-Projected-FCF is ranked worse than 90.57% of 106
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.435
vs SHC: 6.43
Sotera Health Co (NAS:SHC) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Sotera Health Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
18.98
/
2.3738168078085
=
8.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotera Health Co Intrinsic Value: Projected FCF Related Terms
Sotera Health Co Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotera Health Co Intrinsic Value: Projected FCF Chart
SHC vs RDNT, BLLN, ADPT: Intrinsic Value: Projected FCF Comparison
For the Diagnostics & Research subindustry, Sotera Health Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co Price-to-Projected-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's Price-to-Projected-FCF falls into.
Sotera Health Co Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $2.95 mean?
Sotera Health Co (SHC) has a Intrinsic Value: Projected FCF of $2.95 as of Sep. 15, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Sotera Health Co and its competitors. According to the industry distribution chart, Sotera Health Co ranks #96 out of 106 companies in the Medical Diagnostics & Research industry, placing it in the top 90.6%.
Is Sotera Health Co's Intrinsic Value: Projected FCF too high?
Sotera Health Co's current Intrinsic Value: Projected FCF is $2.95. The Medical Diagnostics & Research industry median Intrinsic Value: Projected FCF is 1.44. Sotera Health Co's value of $2.95 is 105.6% above this industry median. Based on the distribution chart, Sotera Health Co ranks #96 out of 106 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Sotera Health Co has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's Intrinsic Value: Projected FCF compare to RDNT and BLLN?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #96 out of 106 companies for Intrinsic Value: Projected FCF. This places Sotera Health Co in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.44. Sotera Health Co's value of $2.95 is 105.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Diagnostics & Research company?
The median Intrinsic Value: Projected FCF among Medical Diagnostics & Research companies is 1.44, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotera Health Co's current Intrinsic Value: Projected FCF of $2.95 is 105.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Sotera Health Co and its competitors. For the Medical Diagnostics & Research industry, the median Intrinsic Value: Projected FCF is 1.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotera Health Co's current Intrinsic Value: Projected FCF is $2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $16.45, compared to a current price of $18.98 — trading 15.4% above its estimated fair value. The current Intrinsic Value: Projected FCF is $2.95 and 105.6% above the Medical Diagnostics & Research industry median of 1.44. Sotera Health Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Sotera Health Co (SHC), the current Intrinsic Value: Projected FCF is $2.95 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $18.98 is trading 15.4% above its estimated GF Value™ of $16.45.
GuruFocus considers Sotera Health Co to be Modestly Overvalued.
Key valuation signals for SHC:
Intrinsic Value: Projected FCF: $2.95
GF Value™: $16.45 vs. price of $18.98 (15.4% above fair value)
Industry Position: 105.6% above the Medical Diagnostics & Research median (#96 of 106)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
76GF Score
Get the complete analysis for SHC
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
